Gene Therapy for Cancer (Cancer Drug Discovery and Development) pdf epub mobi txt 电子书下载 2026

简体网页||繁体网页

☆☆☆☆☆

出版者:Humana Press

作者:Hunt, Kelly K., M.D. (EDT)/ Vorburger, Stephen A., M.D. (EDT)/ Swisher, Stephen G., M.D. (EDT)

出品人:

页数:600

译者:

出版时间:2007-02-02

价格:USD 189.00

装帧:Hardcover

isbn号码:9781588294722

丛书系列:

图书标签:

Gene Therapy
Cancer
Drug Discovery
Drug Development
Oncology
Molecular Biology
Biotechnology
Precision Medicine
Targeted Therapy
Immunotherapy

下载链接在页面底部

facebook linkedin mastodon messenger pinterest reddit telegram twitter viber vkontakte whatsapp 复制链接

想要找书就要到本本书屋

onlinetoolsland.com

立刻按 ctrl+D收藏本页

你会得到大惊喜!!

具体描述

The three sections of this volume present currently available cancer gene therapy techniques. Part I describes the various aspects of gene delivery. In Part II, the contributors discuss strategies and targets for the treatment of cancer. Finally, in Part III, experts discuss the difficulties inherent in bringing gene therapy treatment for cancer to the clinic. This book will prove valuable as the volume of preclinical and clinical data continues to increase.

Innovative Approaches in Oncological Therapeutics: Beyond the Horizon of Gene Therapy A Comprehensive Exploration of Next-Generation Cancer Treatments and Drug Development Paradigms Book Overview: This volume delves into the rapidly evolving landscape of oncology, focusing intently on therapeutic strategies that complement or extend beyond the established frontiers of gene therapy. Recognizing the profound impact of genetic and molecular alterations in cancer pathogenesis, this book pivots to examine the cutting-edge advancements in targeted small-molecule inhibitors, novel immunotherapeutic modalities, sophisticated drug delivery systems, and the integration of artificial intelligence and systems biology in preclinical and clinical drug development. It is meticulously structured to provide researchers, pharmaceutical scientists, clinicians, and advanced students with a deep, critical understanding of where the field is heading, offering detailed analyses of mechanisms of action, translational challenges, and future prospects across various solid and hematological malignancies. --- Part I: Precision Medicine and Targeted Modalities This section establishes the foundation by analyzing the progress made in rational drug design targeting specific oncogenic drivers. We move beyond broad-spectrum chemotherapy to dissect the intricacies of molecularly targeted agents currently revolutionizing patient care. Chapter 1: The Evolution of Kinase Inhibitor Design and Resistance Management A detailed examination of Type I, II, and allosteric kinase inhibitors, focusing on their structural biology and structure-activity relationship (SAR) optimization. The chapter dedicates significant attention to acquired drug resistance mechanisms—including off-target activation, mutation of the binding pocket, and bypass signaling activation—and the development of next-generation inhibitors specifically designed to overcome these hurdles (e.g., covalent inhibitors, reversible inhibitors designed for specific resistance mutations). Case studies are drawn from BCR-ABL positive leukemias and EGFR-driven lung adenocarcinomas, highlighting the iterative nature of small-molecule drug discovery. Chapter 2: Targeting Protein-Protein Interactions (PPIs) for Undruggable Targets This chapter explores the considerable challenge of targeting PPIs, historically considered intractable due to their large, flat interaction surfaces. We review recent successes in developing small-molecule and peptidomimetic inhibitors against critical oncogenic hubs like the MYC/MAX/MNT axis, the MDM2-p53 interaction, and the Bcl-2 family. Emphasis is placed on conformational constraint strategies, conformational selection models, and the use of conformational analysis techniques (e.g., NMR, HDX-MS) to guide inhibitor design against dynamic protein interfaces. Chapter 3: Antibody-Drug Conjugates (ADCs): Refining the Payload and Linker Chemistry A comprehensive review of the second and third generations of ADCs. The focus shifts from early, non-cleavable linkers to sophisticated, cleavable linkers that enable targeted release in the tumor microenvironment (e.g., pH-sensitive hydrazones, enzyme-cleavable peptides). We analyze the spectrum of cytotoxic payloads—from auristatins and maytansinoids to novel tubulin polymerization inhibitors and DNA damaging agents—and discuss strategies for optimizing the drug-to-antibody ratio (DAR) to balance efficacy and systemic toxicity. Furthermore, emerging concepts like conditional activation strategies using cleavable moieties triggered only by specific tumor biomarkers are explored. --- Part II: Immunotherapy Beyond Checkpoint Blockade While immune checkpoint inhibitors (ICIs) have transformed cancer treatment, significant challenges remain, particularly in 'cold' tumors and overcoming resistance. This section examines the burgeoning field of non-ICI immunotherapies and next-generation cellular therapies. Chapter 4: Agonist and Modulatory Strategies for Immune Activation This chapter explores agents designed to actively stimulate the immune response rather than simply relieve inhibition. Detailed analysis is provided on agonists targeting co-stimulatory receptors such as OX40, 4-1BB (CD137), and CD40. The complexities of designing functional agonists—balancing receptor clustering requirements with systemic toxicity profiles—are discussed, including the use of trivalent formats and trimerization scaffolds to enhance signal transduction in vivo. Chapter 5: Natural Killer (NK) Cell Therapy and Bispecific Engagers Focusing on innate immunity, this section details the engineering of NK cells for enhanced tumor recognition and cytotoxicity. We review the development of NK cell engagers, including NK-cell activating bispecific antibodies (NKCEs) that simultaneously bind tumor antigens and activating receptors on NK cells. The challenges of maintaining NK cell persistence and overcoming inhibitory signals within the tumor microenvironment are critically evaluated. Chapter 6: Tumor-Infiltrating Lymphocyte (TIL) Therapy Optimization Moving past adoptive T-cell transfer (ACT), this chapter dissects the optimization protocols for TIL cultivation, selection, and expansion. Emphasis is placed on methodologies for isolating high-avidity, stem-like TIL populations and strategies to mitigate exhaustion during ex vivo expansion. Comparisons are drawn between TIL responses in melanoma versus difficult-to-treat solid tumors like pancreatic and ovarian cancers. --- Part III: Drug Delivery, Microenvironment, and Pharmacokinetics Effective cancer therapy relies heavily on getting the therapeutic agent to the target site at the correct concentration, avoiding healthy tissues. This section addresses the advanced engineering required for optimal biodistribution. Chapter 7: Nanoparticle Formulation for Enhanced Tumor Penetration A deep dive into passive (EPR effect exploitation) and active targeting strategies utilizing polymeric micelles, liposomes, and inorganic nanoparticles. The discussion covers surface engineering to modulate opsonization and clearance, and strategies for achieving deep tumor penetration by managing interstitial fluid pressure (IFP) and enhancing convection-enhanced delivery (CED) mechanisms, particularly in desmoplastic tumors. Chapter 8: Modulating the Tumor Microenvironment (TME) for Therapeutic Synergy This critical chapter explores therapeutic interventions aimed at reprogramming the TME to become more permissive to cytotoxic agents. Specific focus areas include the normalization of tumor vasculature, the depletion or reprogramming of cancer-associated fibroblasts (CAFs), and strategies to reverse the immunosuppressive effects orchestrated by tumor-associated macrophages (TAMs) and regulatory T cells (Tregs). The use of antifibrotic agents in combination regimens is examined. Chapter 9: Pharmacokinetics/Pharmacodynamics (PK/PD) Modeling for Combination Regimens This chapter moves into the quantitative aspects of development. It details advanced allometric scaling, population PK/PD modeling, and physiologically based pharmacokinetic (PBPK) modeling required when combining targeted agents with immunotherapies. The necessity of integrating exposure-response data across different species to predict human efficacy and toxicity in late-stage trials is emphasized. --- Part IV: Integrative Oncology and Future Development Platforms The final section looks forward, integrating computational power and novel preclinical models into the drug discovery pipeline. Chapter 10: Systems Biology and Network Pharmacology in Drug Repurposing An analysis of how large-scale 'omics' data (genomics, proteomics, metabolomics) are integrated using network biology approaches. This section details methods for identifying novel combination strategies by mapping drug targets onto functional biological pathways, thereby uncovering synergistic relationships between existing, FDA-approved drugs and novel agents for difficult-to-treat indications. Chapter 11: Advanced Preclinical Modeling: Organoids and Humanized Mice This chapter critically evaluates the shift away from traditional 2D cell cultures toward three-dimensional organoid and spheroid models derived directly from patient biopsies. The utility of these systems for high-throughput drug sensitivity screening and personalized medicine strategies is assessed, alongside the role of sophisticated humanized mouse models in evaluating complex in vivo immune interactions relevant to novel immunotherapies. Chapter 12: Machine Learning in Hit-to-Lead Optimization and Toxicity Prediction Exploring the transformative role of Artificial Intelligence (AI) and Machine Learning (ML) in accelerating the discovery pipeline. Topics include the use of deep learning for structure-based virtual screening, predictive quantitative structure-activity relationship (QSAR) modeling for optimizing physicochemical properties, and advanced algorithms trained on large toxicity datasets to filter out potentially problematic compounds early in the discovery phase, thereby reducing preclinical attrition rates. --- Conclusion: Innovative Approaches in Oncological Therapeutics serves as an essential reference that captures the dynamic interplay between molecular understanding, engineering prowess, and computational biology in the modern pursuit of cancer cures. It offers a clear roadmap charting pathways through the complex terrain of next-generation drug development, highlighting areas ripe for transformative research and clinical application.

作者简介

目录信息

读后感

评分☆☆☆☆☆

用户评价

评分☆☆☆☆☆

作为一名在肿瘤科临床一线工作的医生，我一直在寻找能够帮助我理解并应用最新治疗手段的专业书籍。Gene Therapy for Cancer (Cancer Drug Discovery and Development) 这个书名，立刻吸引了我的注意。在多年的临床实践中，我深切体会到传统癌症治疗方法的局限性，以及患者对更有效、更少副作用的治疗方式的迫切需求。基因疗法，作为一种革命性的治疗模式，无疑为癌症治疗带来了新的希望。我希望这本书能够详细介绍当前基因疗法在各种癌症类型中的应用现状，包括其潜在的治疗效果、安全性以及不良反应。我特别关注书中关于药物发现和开发的部分，因为了解药物的研发过程，有助于我更好地理解药物的作用原理，从而在临床实践中更精准地选择和应用这些疗法。我想知道，这本书会如何解析基因疗法的临床前研究，包括体外和体内模型的建立，以及在不同临床试验阶段（I期、II期、III期）的考量因素和成功标准。同时，我也希望书中能够探讨基因疗法与其他治疗模式（如化疗、放疗、免疫疗法）的联合应用策略，以及如何克服目前基因疗法在递送效率、特异性、以及免疫原性等方面存在的挑战。

评分☆☆☆☆☆

这本书的份量，从书脊的厚度就能感受到，它绝非一本浅尝辄止的科普读物，而是一部真正深入探讨基因疗法在癌症治疗中复杂性和潜力的学术专著。我是一名对癌症生物学有着浓厚兴趣的科研工作者，一直在关注着基因疗法这一新兴领域的发展。市面上关于基因疗法的书籍并不少，但往往侧重于理论介绍，或是过于技术化，而这本书的标题，Gene Therapy for Cancer (Cancer Drug Discovery and Development)，似乎在两者之间找到了一个精妙的平衡点。我迫切希望它能够提供关于基因疗法作用机制的深入解读，从分子层面解释其如何靶向癌细胞、如何诱导细胞凋亡，或者如何激活免疫系统来清除肿瘤。同时，我也非常关注药物发现和开发这一环节。基因疗法与传统的小分子药物或抗体药物在研发路径上存在显著差异，我渴望了解在这本书中，作者会如何详细阐述基因疗法药物的发现策略，包括基因编辑技术、病毒载体设计、非病毒递送系统，以及在临床前和临床试验中遇到的挑战与解决方案。我期待这本书能够提供最新的研究数据、成功的案例分析，甚至是一些尚未公开的研究方向，为我的科研工作提供宝贵的启示和灵感。

评分☆☆☆☆☆

我是一名生物学专业的学生，正在积极地为未来的学术研究和职业发展做准备。在众多学科领域中，癌症生物学和基因疗法是我特别感兴趣的方向。当我看到Gene Therapy for Cancer (Cancer Drug Discovery and Development) 这本书时，我立刻意识到它可能是我深入了解这一领域的绝佳资源。我希望这本书能够提供一个系统性的框架，帮助我理解基因疗法在癌症治疗中的核心概念、关键技术以及发展历程。我渴望了解更具体的内容，例如，书中会详细阐述哪些类型的基因疗法？例如，基因添加、基因编辑（如CRISPR-Cas9）、基因沉默（如siRNA）、以及细胞疗法（如CAR-T细胞疗法）在癌症治疗中的具体应用和原理。我也非常想知道，药物发现和开发这一环节是如何具体展开的。这包括如何确定潜在的治疗靶点，如何设计和优化基因载体（病毒载体或非病毒载体），如何进行体外和体内实验来评估其疗效和安全性，以及在临床试验中需要克服的伦理、法规和技术障碍。这本书能够为我提供一个扎实的理论基础，并让我对这一前沿领域的研究动态有更清晰的认识，为我未来的学习和研究打下坚实的基础。

评分☆☆☆☆☆

我是一名对健康生活方式和疾病预防有着深刻理解的健康博主。虽然我的主要关注点是预防，但我深知，对于已经患上癌症的患者而言，先进的治疗手段至关重要。Gene Therapy for Cancer (Cancer Drug Discovery and Development) 这个书名，对我来说，代表着一种全新的、更具希望的治疗方向。我希望这本书能够以一种相对浅显易懂的方式，向我的读者们介绍基因疗法在癌症治疗中的基本原理。这包括，基因疗法是如何针对癌症的根本原因——基因突变的，以及它如何与传统的治疗方法（如手术、化疗、放疗）有所不同。我尤其关注书中关于药物发现和开发的部分，我想了解，那些针对癌症的基因疗法，是如何被科学家们研发出来的。它会涉及到哪些技术，例如，是如何找到引起癌症的特定基因，又是如何将正确的基因“送入”癌细胞，或者如何“关闭”那些有害的基因。我希望能在这本书中，找到一些关于基因疗法安全性和有效性的信息，以及它可能带来的副作用，以便我能够更全面地向我的听众介绍这个新兴的治疗领域，并强调科学研究和医学进步的重要性。

评分☆☆☆☆☆

我是一名对未来科技发展趋势有着敏锐洞察力的科技评论员。Gene Therapy for Cancer (Cancer Drug Discovery and Development) 这个书名，让我看到了科技如何深刻地改变人类的健康和医疗保健。我希望这本书能够提供一个宏观的视野，让我能够理解基因疗法在癌症治疗领域所扮演的关键角色，以及它将如何重塑未来的医疗格局。我关注的重点在于药物发现和开发这一环节，因为这直接体现了科技转化为现实生产力的能力。我想了解，书中会如何剖析基因疗法药物的研发流程，例如，是如何利用大数据和人工智能来加速靶点发现，如何设计和优化新的基因递送载体，以及如何在临床试验中利用先进的生物标记物来评估疗效。我期待这本书能够展现出基因疗法研发的创新性和颠覆性，包括那些可能改变游戏规则的新技术和新策略。同时，我也希望书中能够探讨基因疗法在癌症治疗中面临的挑战，例如，成本、可及性、以及伦理问题，这些都是未来技术发展和应用过程中需要解决的关键问题。

评分☆☆☆☆☆

我是一名有着丰富投资经验的风险投资家，长期关注生物医药和生命科学领域的投资机会。Gene Therapy for Cancer (Cancer Drug Discovery and Development) 这个书名，立刻引起了我的注意，它精准地指向了当下最热门、最具潜力的一个细分领域。我一直认为，基因疗法是解决癌症这一世界性难题的终极方向之一，而与药物发现和开发相关的深入探讨，则直接关系到投资的价值和回报。我希望这本书能够提供一个高屋建瓴的视角，让我能够全面地了解基因疗法在癌症治疗领域的整体格局。这包括对当前基因疗法市场规模、增长趋势、以及主要参与者的分析。我更希望能深入了解药物发现和开发的关键环节。例如，书中会如何分析基因疗法药物的研发管线，评估不同技术平台（如慢病毒、腺相关病毒、mRNA疗法、基因编辑技术）的优劣势，以及其在不同癌症类型中的应用前景。我还会密切关注书中对临床试验数据、监管审批流程、以及知识产权保护等方面的解读，这些都是我进行投资决策的重要考量因素。

评分☆☆☆☆☆

我是一名对生物技术和医学前沿充满热情的业余爱好者，常常会花时间阅读一些与我兴趣相关的书籍，以拓展我的视野。Gene Therapy for Cancer (Cancer Drug Discovery and Development) 这个书名，听起来就非常吸引人，它将“基因疗法”和“癌症”这两个当下最受关注的领域结合起来，并且加上了“药物发现和发展”这样一个更具实践意义的副标题，这让我觉得这本书的内容会非常丰富且有深度。我之所以被这本书吸引，是因为我对生命的奥秘以及如何通过科学手段来解决人类健康问题感到着迷。基因疗法，听起来就像是能够从根本上解决问题的方法，它能够修复甚至改变我们身体的“程序”，从而对抗疾病。我希望这本书能够以一种相对易懂的方式，向我解释基因疗法是如何工作的，它有哪些不同的技术手段，以及这些技术是如何被应用到癌症治疗中的。同时，我也非常好奇，从一个想法到一个真正能够应用于患者身上的药物，需要经历哪些漫长而复杂的过程。这本书的副标题，Cancer Drug Discovery and Development，让我有理由相信，它会详细介绍药物的研发流程，包括早期的科学探索，到实验室的研究，再到临床试验的漫漫长路，以及其中可能遇到的各种困难和挑战。

评分☆☆☆☆☆

我是一名对科学史和医学发展充满兴趣的普通读者。从历史的角度来看，癌症治疗经历了漫长而曲折的探索过程，而基因疗法的出现，无疑是医学史上的一次重大突破。Gene Therapy for Cancer (Cancer Drug Discovery and Development) 这个书名，让我看到了人类在与癌症斗争中取得的最新、最前沿的进展。我希望这本书能够以一种生动而引人入胜的方式，讲述基因疗法在癌症治疗领域的发展故事。这包括基因疗法概念的起源，早期研究的艰辛，以及关键技术的突破，例如基因工程、分子生物学以及病毒学的发展是如何推动基因疗法取得进展的。同时，我也想了解，在药物发现和开发的过程中，那些伟大的科学家和工程师们是如何克服重重困难，将一个个实验室里的奇思妙想，转化为能够拯救生命的实际疗法。书中是否会穿插一些激动人心的科研故事，或是关于那些在临床试验中勇敢尝试新疗法的患者的经历？我希望能在这本书中，感受到科学探索的力量，以及人类智慧在对抗疾病面前所展现出的无穷潜力。

评分☆☆☆☆☆

这本书，从封面设计上就透露着一股严谨又充满希望的气息。深邃的蓝色背景，仿佛浩瀚的宇宙，点缀着精巧的DNA双螺旋结构，以及那些代表着生命希望的细胞模型。光是看到这画面，就足以激发我深入探索基因疗法在癌症治疗领域奥秘的冲动。我一直对医学的前沿领域充满好奇，而基因疗法无疑是其中最令人振奋的方向之一。它不仅仅是治疗疾病，更像是在重新编写生命的密码，修复那些因错误而引发的病变。这本书的名字，Gene Therapy for Cancer (Cancer Drug Discovery and Development)，直接点明了其核心主题，让我迫不及待地想了解，究竟是什么样的研究和发展，正在为无数癌症患者带来新的曙光。我期待这本书能为我打开一扇通往未来癌症治疗的大门，让我能够更清晰地认识到，基因疗法是如何从理论走向实践，又是如何一步步地改变着我们对抗癌症的策略。我尤其想知道，那些在实验室里孕育出的创新疗法，是如何在药物发现和开发的过程中，最终转化为能够挽救生命的实际应用。这本书的副标题，Cancer Drug Discovery and Development，也暗示了其内容的深度和广度，它不仅仅停留在理论层面，更会深入到实际的药物研发流程，这对我来说具有极大的吸引力。我希望能在这本书中，找到关于最新研究进展、临床试验数据、以及未来发展趋势的详尽阐述。

评分☆☆☆☆☆

我是一名对科学研究的伦理和哲学层面有着深入思考的哲学家。Gene Therapy for Cancer (Cancer Drug Discovery and Development) 这个书名，让我看到了科学技术在解决人类重大问题上的力量，同时也引发了我对于生命、健康以及人与自然关系的进一步思考。我希望这本书能够从更深层次的角度，探讨基因疗法在癌症治疗领域的意义。这不仅包括其科学原理和技术手段，更包括其对人类生命伦理的影响。我希望书中能够深入讨论基因疗法在药物发现和开发过程中所涉及的伦理考量，例如，基因改造的边界在哪里？如何平衡疗效与潜在的风险？在追求治愈癌症的过程中，我们应该如何对待生命？此外，我也对基因疗法与人类进化的关系，以及它可能对未来社会带来的深远影响感兴趣。这本书能够提供一个丰富的案例，让我从哲学角度去审视基因疗法这一强大的科学工具，并思考它在塑造人类未来健康图景中所扮演的角色。

评分☆☆☆☆☆